Evotec AG And Pierre Fabre Sign Multi-Year Compound Management Agreement

HAMBURG, Germany--(BUSINESS WIRE)--Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today announced a multi-year compound management agreement with Pierre Fabre Laboratories, the 2nd largest private French pharmaceutical group.

Under the terms of the agreement, Evotec will manage Pierre Fabre's compound collection (individual compounds and collection plates) out of its state-of-the-art compound management facility in Toulouse, France. The agreement covers an initial period of five years.

Laurent Audoly, Pierre Fabre Pharmaceuticals R&D Director, commented: "We are delighted to announce this first partnership with Evotec who has become a leading player in the Toulouse drug discovery ecosystem. With its significant expertise in the field of compound management, Evotec will undoubtedly be an important partner for Pierre Fabre to accelerate its discovery and development pace in the fields of oncology, dermatology and CNS."

Dr Mario Polywka, Chief Operating Officer of Evotec, stated: "We welcome Pierre Fabre as another partner who has entrusted their complete compound management needs to our state-of-the-art operation in Toulouse. This collaboration further validates our strategy to establish a state-of-the-art compound management operation out of Toulouse for the European market and cements our position as the world leader in outsourced compound management. We look forward to a long and successful partnership with Pierre Fabre."

No financial details were disclosed.


Pierre Fabre is a private pharmaceuticals and dermo-cosmetics company founded in 1962 by Mr. Pierre Fabre. Its turnover reached over 2.2 billion Euros* in 2015, spread over 130 countries. The company is structured around two divisions: Pharmaceuticals (prescription drugs, consumer health care) and Dermo-cosmetics (including the Europe and Asia market-leader brand Eau Thermale Avène). Pierre Fabre employs some 11,000 people worldwide and owns subsidiaries in 43 countries. In 2015, the company allocated 16 percent of its pharmaceuticals sales to R&D with a focus on 4 therapeutic areas: oncology, dermatology, CNS and consumer health care. Within the framework of their Open Innovation strategy, Pierre Fabre Laboratories have always developed durable and valuable scientific partnerships with innovators from public research institutions (CNRS, Inserm, .), faculties and universities (Ecole Polytechnique de Lausanne, Université de Saclay, .), international pharmaceutical laboratories (Allergan, Abbvie, Maruho, .) and biotech companies (Array, BioPharma, AbCheck, Cellectar, .). Through the Group's controlling company Pierre Fabre Participations, Pierre Fabre is 86% owned by the Pierre Fabre Foundation, a recognized public-interest organization since 1999, around 8% by the company's employees while balance is held as treasury stock.

To learn more, please go to www.pierre-fabre.com/en

*2015 financial results currently being audited


Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery (EVT Execute).The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, pain, metabolic diseases as well as oncology, inflammation and infectious diseases. On this basis, Evotec has built a broad and deep pipeline of more than 70 partnered product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term discovery alliances with partners including Bayer, CHDI or UCB and development partnerships with e.g. Janssen Pharmaceuticals in the field of Alzheimer's disease, with MedImmune and Sanofi in the field of diabetes, with Pfizer in the field of organ fibrosis and with Second Genome in the field of inflammatory diseases. For additional information please go to www.evotec.com.

FORWARD LOOKING STATEMENTS - Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.

Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222




ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart; Terminbörse EUREX

Evotec AG:
Gabriele Hansen, +49.(0)40.56081-255
VP Corporate Communications & Investor Relations

Back to news